Orchestra BioMed Holdings Inc. (OBIO)
NASDAQ: OBIOHealth Care Medicinal Chemicals and Botanical Products USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OBIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $517.88M
- EPS (TTM)
- -$0.75
- Dividend yield
- None
- 52-week range
- 3.46 – 7.83
- Day range
- 6.47 – 7.14
- Volume / Avg
- 554.32K / 420.19K
- Beta
- —
- Shares outstanding
- 78.70M
52-week range
OBIO stock today
Orchestra BioMed (OBIO) closed at $6.58 on Nov 20, down 6.00% (-$0.42), versus the S&P 500's 3.70% decline. Shares are 15.9% below their 52-week high of $7.83, set on Nov 18, 2026 and 90.2% above the 52-week low of $3.46, in the middle of the past year's range. OBIO is up 58.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 45.3%.
Orchestra BioMed has posted a net loss over the last twelve months (EPS of -$0.75), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Orchestra BioMed
Company profileOrchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- CEO
- Mr. David P. Hochman
- Headquarters
- New Hope, PA
- Employees
- 86
- IPO year
- 2020
- Website
- orchestrabiomed.com
Financial highlights
Full financialsIn fiscal 2025, Orchestra BioMed generated $33.5 million in revenue, up 1169.2% from fiscal 2024. Orchestra BioMed reported a net loss of $52.7 million, compared with a loss of $61.0 million a year earlier. Gross margin was 99.4% (up from 92.3%) and operating margin -154.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $33.48M | $2.64M | $2.76M | $3.53M | — |
| Growth | +1169.22% | -4.42% | -21.88% | — | — |
| Net income | $-52.70M | $-61.02M | $-49.12M | $-33.61M | $-378.75K |
| EPS (diluted) | $-1.11 | $-1.66 | $-1.48 | $-2.24 | $-0.02 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$13.29+101.98%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.30 vs $-0.40
- Surprise
- +25.00%
OBIO news
All OBIO news- Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare ConferenceGlobeNewswire
- Orchestra BioMed Reports Third Quarter 2026 Financial Results and Highlights Recent Business UpdatesGlobeNewswire
- Orchestra BioMed Holdings, Inc. Closes $86.3 Million Public Offering of Common StockNasdaq
- Orchestra BioMed Prices $75 Mln Offering At $5/Shr To Fund Pivotal TrialsNasdaqMDT, OBIO, LEN.B
- Orchestra BioMed Announces Pricing of Public OfferingGlobeNewswire
- Guardant Health (GH) Reports Q3 Loss, Tops Revenue EstimatesNasdaqGH, OBIO
- Orchestra BioMed Announces Virtue SAB Presentation at TCT 2026GlobeNewswire
- Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SABGlobeNewswire
Orchestra BioMed peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SNDLSNDL Inc. | 1.17 | -5.65% | $285.20M | vs OBIO |
| TLRYTilray Brands Inc. | 1.89 | -8.70% | $279.32M | vs OBIO |
| ACBAurora Cannabis Inc. | 4.16 | -2.35% | $273.50M | vs OBIO |
| USNAUSANA Health Sciences Inc. | 12.94 | -1.67% | $239.24M | vs OBIO |
| MDWDMediWound Ltd. | 13.59 | +0.37% | $195.56M | vs OBIO |
| CGCCanopy Growth Corporation | 0.427 | -9.97% | $191.99M | vs OBIO |
| NAGENiagen Bioscience Inc. | 1.84 | -1.60% | $145.72M | vs OBIO |
| GLASGlass House Brands Inc. Subordinate Voting Shares | 1.18 | -2.48% | $118.11M | vs OBIO |
Indexes, lists and sector
Orchestra BioMed stock FAQ
What is Orchestra BioMed's stock price today?
OBIO last traded at $6.58 as of Nov 20, 4:00 PM EST, down 6.00% on the day. Prices are delayed at least 15 minutes.
Who is Orchestra BioMed's CEO?
Mr. David P. Hochman is the chief executive officer of Orchestra BioMed Holdings Inc., which has about 86 employees.
What is the OBIO 52-week high?
The 52-week high for OBIO is $7.83 and the 52-week low is $3.46. The stock is currently 15.9% below its high.